Efficacy and safety of monthly ibandronate in men with low bone density

Eric Orwoll, Neil C. Binkley, E. Michael Lewiecki, Ugis Gruntmanis, Michael A. Fries, Gorana Dasic

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Introduction: Monthly oral ibandronate is indicated for the prevention and treatment of osteoporosis in postmenopausal women. The STudy Researching Osteoporosis iN Guys (STRONG) investigated the efficacy and safety of 150-mg monthly oral ibandronate in men with primary, idiopathic, or hypogonadism-related low bone density. Methods: STRONG was a 1-year, placebo-controlled, randomized (2 ibandronate: 1 placebo), double-blind study that enrolled ambulatory men > 30 years with baseline femoral neck (FN) bone mineral density (BMD) T-scores > 4.0 at any site assessed by dual-energy X-ray absorptiometry. The primary endpoint was mean percent change from baseline in LS BMD at 1 year (intent-to-treat [ITT] population). Secondary endpoints included mean BMD changes from baseline at the FN, total hip (TH), and trochanter (TR) and changes in bone turnover markers (BTMs), as measured by the bone resorption marker serum C-terminal telopeptide of type 1 collagen (sCTX) and the bone formation marker bone-specific alkaline phosphatase (BSAP). All men received twice daily calcium carbonate (1000 mg/day) and vitamin D (400 IU/day). Changes in BMD for treatment groups were compared using analysis of covariance with treatment, investigative site, and baseline testosterone as factors and baseline BMD as a covariate. Results: The ITT population consisted of 132 men; 47 received placebo and 85 received monthly ibandronate. Men who received ibandronate achieved greater increases in LS BMD at 12 months than those who received placebo (3.5% vs. 0.9%, respectively; difference, 2.6; p

Original languageEnglish (US)
Pages (from-to)970-976
Number of pages7
JournalBone
Volume46
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Bone Density
Safety
Placebos
Femur Neck
Osteoporosis
Postmenopausal Osteoporosis
Hypogonadism
Calcium Carbonate
Bone Remodeling
Photon Absorptiometry
Bone Resorption
Collagen Type I
ibandronic acid
Double-Blind Method
Osteogenesis
Vitamin D
Femur
Population
Alkaline Phosphatase
Testosterone

Keywords

  • Bone density
  • Ibandronate
  • Men
  • Osteoporosis
  • Treatment

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Orwoll, E., Binkley, N. C., Lewiecki, E. M., Gruntmanis, U., Fries, M. A., & Dasic, G. (2010). Efficacy and safety of monthly ibandronate in men with low bone density. Bone, 46(4), 970-976. https://doi.org/10.1016/j.bone.2009.12.034

Efficacy and safety of monthly ibandronate in men with low bone density. / Orwoll, Eric; Binkley, Neil C.; Lewiecki, E. Michael; Gruntmanis, Ugis; Fries, Michael A.; Dasic, Gorana.

In: Bone, Vol. 46, No. 4, 04.2010, p. 970-976.

Research output: Contribution to journalArticle

Orwoll, E, Binkley, NC, Lewiecki, EM, Gruntmanis, U, Fries, MA & Dasic, G 2010, 'Efficacy and safety of monthly ibandronate in men with low bone density', Bone, vol. 46, no. 4, pp. 970-976. https://doi.org/10.1016/j.bone.2009.12.034
Orwoll E, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010 Apr;46(4):970-976. https://doi.org/10.1016/j.bone.2009.12.034
Orwoll, Eric ; Binkley, Neil C. ; Lewiecki, E. Michael ; Gruntmanis, Ugis ; Fries, Michael A. ; Dasic, Gorana. / Efficacy and safety of monthly ibandronate in men with low bone density. In: Bone. 2010 ; Vol. 46, No. 4. pp. 970-976.
@article{ba72d376a22b4ddc93c9a48b3858f3ed,
title = "Efficacy and safety of monthly ibandronate in men with low bone density",
abstract = "Introduction: Monthly oral ibandronate is indicated for the prevention and treatment of osteoporosis in postmenopausal women. The STudy Researching Osteoporosis iN Guys (STRONG) investigated the efficacy and safety of 150-mg monthly oral ibandronate in men with primary, idiopathic, or hypogonadism-related low bone density. Methods: STRONG was a 1-year, placebo-controlled, randomized (2 ibandronate: 1 placebo), double-blind study that enrolled ambulatory men > 30 years with baseline femoral neck (FN) bone mineral density (BMD) T-scores > 4.0 at any site assessed by dual-energy X-ray absorptiometry. The primary endpoint was mean percent change from baseline in LS BMD at 1 year (intent-to-treat [ITT] population). Secondary endpoints included mean BMD changes from baseline at the FN, total hip (TH), and trochanter (TR) and changes in bone turnover markers (BTMs), as measured by the bone resorption marker serum C-terminal telopeptide of type 1 collagen (sCTX) and the bone formation marker bone-specific alkaline phosphatase (BSAP). All men received twice daily calcium carbonate (1000 mg/day) and vitamin D (400 IU/day). Changes in BMD for treatment groups were compared using analysis of covariance with treatment, investigative site, and baseline testosterone as factors and baseline BMD as a covariate. Results: The ITT population consisted of 132 men; 47 received placebo and 85 received monthly ibandronate. Men who received ibandronate achieved greater increases in LS BMD at 12 months than those who received placebo (3.5{\%} vs. 0.9{\%}, respectively; difference, 2.6; p",
keywords = "Bone density, Ibandronate, Men, Osteoporosis, Treatment",
author = "Eric Orwoll and Binkley, {Neil C.} and Lewiecki, {E. Michael} and Ugis Gruntmanis and Fries, {Michael A.} and Gorana Dasic",
year = "2010",
month = "4",
doi = "10.1016/j.bone.2009.12.034",
language = "English (US)",
volume = "46",
pages = "970--976",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of monthly ibandronate in men with low bone density

AU - Orwoll, Eric

AU - Binkley, Neil C.

AU - Lewiecki, E. Michael

AU - Gruntmanis, Ugis

AU - Fries, Michael A.

AU - Dasic, Gorana

PY - 2010/4

Y1 - 2010/4

N2 - Introduction: Monthly oral ibandronate is indicated for the prevention and treatment of osteoporosis in postmenopausal women. The STudy Researching Osteoporosis iN Guys (STRONG) investigated the efficacy and safety of 150-mg monthly oral ibandronate in men with primary, idiopathic, or hypogonadism-related low bone density. Methods: STRONG was a 1-year, placebo-controlled, randomized (2 ibandronate: 1 placebo), double-blind study that enrolled ambulatory men > 30 years with baseline femoral neck (FN) bone mineral density (BMD) T-scores > 4.0 at any site assessed by dual-energy X-ray absorptiometry. The primary endpoint was mean percent change from baseline in LS BMD at 1 year (intent-to-treat [ITT] population). Secondary endpoints included mean BMD changes from baseline at the FN, total hip (TH), and trochanter (TR) and changes in bone turnover markers (BTMs), as measured by the bone resorption marker serum C-terminal telopeptide of type 1 collagen (sCTX) and the bone formation marker bone-specific alkaline phosphatase (BSAP). All men received twice daily calcium carbonate (1000 mg/day) and vitamin D (400 IU/day). Changes in BMD for treatment groups were compared using analysis of covariance with treatment, investigative site, and baseline testosterone as factors and baseline BMD as a covariate. Results: The ITT population consisted of 132 men; 47 received placebo and 85 received monthly ibandronate. Men who received ibandronate achieved greater increases in LS BMD at 12 months than those who received placebo (3.5% vs. 0.9%, respectively; difference, 2.6; p

AB - Introduction: Monthly oral ibandronate is indicated for the prevention and treatment of osteoporosis in postmenopausal women. The STudy Researching Osteoporosis iN Guys (STRONG) investigated the efficacy and safety of 150-mg monthly oral ibandronate in men with primary, idiopathic, or hypogonadism-related low bone density. Methods: STRONG was a 1-year, placebo-controlled, randomized (2 ibandronate: 1 placebo), double-blind study that enrolled ambulatory men > 30 years with baseline femoral neck (FN) bone mineral density (BMD) T-scores > 4.0 at any site assessed by dual-energy X-ray absorptiometry. The primary endpoint was mean percent change from baseline in LS BMD at 1 year (intent-to-treat [ITT] population). Secondary endpoints included mean BMD changes from baseline at the FN, total hip (TH), and trochanter (TR) and changes in bone turnover markers (BTMs), as measured by the bone resorption marker serum C-terminal telopeptide of type 1 collagen (sCTX) and the bone formation marker bone-specific alkaline phosphatase (BSAP). All men received twice daily calcium carbonate (1000 mg/day) and vitamin D (400 IU/day). Changes in BMD for treatment groups were compared using analysis of covariance with treatment, investigative site, and baseline testosterone as factors and baseline BMD as a covariate. Results: The ITT population consisted of 132 men; 47 received placebo and 85 received monthly ibandronate. Men who received ibandronate achieved greater increases in LS BMD at 12 months than those who received placebo (3.5% vs. 0.9%, respectively; difference, 2.6; p

KW - Bone density

KW - Ibandronate

KW - Men

KW - Osteoporosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77950545056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950545056&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2009.12.034

DO - 10.1016/j.bone.2009.12.034

M3 - Article

C2 - 20060082

AN - SCOPUS:77950545056

VL - 46

SP - 970

EP - 976

JO - Bone

JF - Bone

SN - 8756-3282

IS - 4

ER -